Nxera Pharma Co., Ltd.
SOLTF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $46 | $8,450 | $6,644 | $6,852 |
| % Growth | -99.5% | 27.2% | -3% | – |
| Cost of Goods Sold | $18 | $1,858 | $1,615 | $2,127 |
| Gross Profit | $28 | $6,592 | $5,029 | $4,725 |
| % Margin | 60.4% | 78% | 75.7% | 69% |
| R&D Expenses | $25 | $3,666 | $3,808 | $3,299 |
| G&A Expenses | $0 | $0 | $0 | -$1,031 |
| SG&A Expenses | $26 | $3,865 | $3,701 | $1,207 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $2,238 |
| Other Operating Expenses | $0 | $287 | -$287 | $3,985 |
| Operating Expenses | $51 | $7,818 | $7,222 | $8,491 |
| Operating Income | -$24 | -$1,226 | -$2,193 | -$3,766 |
| % Margin | -51.7% | -14.5% | -33% | -55% |
| Other Income/Exp. Net | $3 | -$340 | $37 | $1,397 |
| Pre-Tax Income | -$21 | -$1,566 | -$2,156 | -$2,369 |
| Tax Expense | -$10 | $811 | $1,396 | $1,034 |
| Net Income | -$11 | -$2,377 | -$760 | -$1,335 |
| % Margin | -24.8% | -28.1% | -11.4% | -19.5% |
| EPS | -0.12 | -26.35 | -8.45 | -14.85 |
| % Growth | 99.5% | -211.8% | 43.1% | – |
| EPS Diluted | -0.12 | -26.35 | -8.45 | -14.86 |
| Weighted Avg Shares Out | 90 | 90 | 90 | 90 |
| Weighted Avg Shares Out Dil | 90 | 90 | 90 | 90 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $37 | $156 |
| Interest Expense | $1 | $1,003 | $0 | $0 |
| Depreciation & Amortization | $7 | $1,095 | $1,082 | $1,003 |
| EBITDA | -$12 | $532 | -$1,111 | -$2,775 |
| % Margin | -26.7% | 6.3% | -16.7% | -40.5% |